CNS FGF21 Gene Therapy for Long-Acting Metabolic Control
Solution Overview
Problem
Current FGF21 therapies for obesity and diabetes suffer from poor pharmacokinetic characteristics, short half-life, susceptibility to degradation, and require frequent administrations, posing a burden to patients and risking immunogenicity, while existing treatments fail to address neuroinflammation's role in cognitive decline and metabolic dysfunction.
Innovation Solution
A gene therapy approach expressing FGF21 in the central nervous system, particularly the hypothalamus, using adeno-associated viral vectors and microRNA target sequences to prevent unwanted expression in organs like the liver and heart, ensuring robust and widespread overexpression in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If engineered FGF21 mimetics are used to extend half-life and improve stability, then the duration of action is improved, but immunogenicity increases causing adverse reactions
Solution Approach 1:
The patent uses native FGF21 amino acid sequence as a template to create modified versions that retain the original protein's low immunogenicity characteristics while improving pharmacokinetic properties through structural modifications rather than complete redesign
Solution Approach 2:
The patent modifies specific amino acid residues in the FGF21 sequence (such as N-terminal extensions or side chain modifications) to extend half-life and improve stability while maintaining the native protein's low immunogenicity profile, achieving parameter optimization without sacrificing biocompatibility
2Duration of action of moving object
If multiple administrations of FGF21 are required to maintain therapeutic effect, then the duration of action is improved, but the complexity of operation increases
Solution Approach 1:
The patent achieves continuous therapeutic action through a single administration by engineering FGF21 variants with extended half-life that maintain effective concentrations in the bloodstream for prolonged periods, eliminating the need for repeated injections and providing continuous metabolic regulation
3Reliability
If FGF21 is administered systemically to treat metabolic disorders, then the therapeutic effect is improved, but harmful effects on specific organs such as heart and liver increase
Solution Approach 1:
The patent employs tissue-specific promoters (such as brain-specific or hypothalamus-specific promoters) to drive FGF21 expression only in target tissues, creating local therapeutic action while avoiding systemic distribution and associated organ toxicity
Solution Approach 2:
The patent uses the central nervous system, particularly the hypothalamus, as an intermediary target organ. By expressing FGF21 in the brain, the therapy indirectly regulates peripheral metabolism through neural and hormonal pathways, avoiding direct exposure of sensitive organs like the heart and liver to high concentrations of FGF21
Data Source
AI summary
Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS).